The Necroptotic Process-related Signature Predicts Immune Infiltration and Drug Sensitivity in Kidney Renal Papillary Cell Carcinoma

Overview

Journal Curr Cancer Drug Targets

Publisher Bentham Science Publishers

Specialty Oncology

Date 2024 Apr 15

PMID 38616744

Authors

Wenfeng Lin

Ruizhi Xue

Hideo Ueki

Peng Huang

Affiliations

Soon will be listed here.

Abstract

Background: It remains controversial whether the current subtypes of kidney renal papillary cell carcinoma (KIRP) can be used to predict the prognosis independently.

Objective: This observational study aimed to identify a risk signature based on necroptotic process- related genes (NPRGs) in KIRP.

Methods: In the training cohort, LASSO regression was applied to construct the risk signature from 158 NPRGs, followed by the analysis of Overall Survival (OS) using the Kaplan-Meier method. The signature accuracy was evaluated by the Receiver Operating Characteristic (ROC) curve, which was further validated by the test cohort. Wilcoxon test was used to compare the expressions of immune-related genes, neoantigen genes, and immune infiltration between different risk groups, while the correlation test was performed between NPRGs expressions and drug sensitivity. Gene set enrichment analysis was used to investigate the NPRGs' signature's biological functions.

Results: We finally screened out 4-NPRGs (BIRC3, CAMK2B, PYGM, and TRADD) for constructing the risk signature with the area under the ROC curve (AUC) reaching about 0.8. The risk score could be used as an independent OS predictor. Consistent with the enriched signaling, the NPRGs signature was found to be closely associated with neoantigen, immune cell infiltration, and immune-related functions. Based on NPRGs expressions, we also predicted multiple drugs potentially sensitive or resistant to treatment.

Conclusion: The novel 4-NPRGs risk signature can predict the prognosis, immune infiltration, and therapeutic sensitivity of KIRP.

References

Marchetti A, Rosellini M, Mollica V, Rizzo A, Tassinari E, Nuvola G . The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory?. Int J Mol Sci. 2021; 22(12). PMC: 8226484. DOI: 10.3390/ijms22126237. View

Xiong S, Zhu W, Li X, Yu Y, Yang K, Zhang L . Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis. Transl Androl Urol. 2021; 10(8):3255-3266. PMC: 8421816. DOI: 10.21037/tau-21-329. View

Muglia V, Prando A . Renal cell carcinoma: histological classification and correlation with imaging findings. Radiol Bras. 2015; 48(3):166-74. PMC: 4492569. DOI: 10.1590/0100-3984.2013.1927. View

Brodziak A, Sobczuk P, Bartnik E, Fiedorowicz M, Porta C, Szczylik C . Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities. Nat Rev Urol. 2019; 16(11):655-673. DOI: 10.1038/s41585-019-0233-z. View

Liu Y, Liu T, Lei T, Zhang D, Du S, Girani L . RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review). Int J Mol Med. 2019; 44(3):771-786. PMC: 6658002. DOI: 10.3892/ijmm.2019.4244. View

Seo J, Nam Y, Kim S, Oh D, Song J . Necroptosis molecular mechanisms: Recent findings regarding novel necroptosis regulators. Exp Mol Med. 2021; 53(6):1007-1017. PMC: 8166896. DOI: 10.1038/s12276-021-00634-7. View

Zhan C, Huang M, Yang X, Hou J . MLKL: Functions beyond serving as the Executioner of Necroptosis. Theranostics. 2021; 11(10):4759-4769. PMC: 7978304. DOI: 10.7150/thno.54072. View

Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K . The role of necroptosis in cancer biology and therapy. Mol Cancer. 2019; 18(1):100. PMC: 6532150. DOI: 10.1186/s12943-019-1029-8. View

Najafov A, Chen H, Yuan J . Necroptosis and Cancer. Trends Cancer. 2017; 3(4):294-301. PMC: 5402749. DOI: 10.1016/j.trecan.2017.03.002. View

10.

Hernandez C, Huebener P, Schwabe R . Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene. 2016; 35(46):5931-5941. PMC: 5119456. DOI: 10.1038/onc.2016.104. View

11.

Yatim N, Jusforgues-Saklani H, Orozco S, Schulz O, Barreira da Silva R, Reis e Sousa C . RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8⁺ T cells. Science. 2015; 350(6258):328-34. PMC: 4651449. DOI: 10.1126/science.aad0395. View

12.

Chen W, Lin W, Wu L, Xu A, Liu C, Huang P . A Novel Prognostic Predictor of Immune Microenvironment and Therapeutic Response in Kidney Renal Clear Cell Carcinoma based on Necroptosis-related Gene Signature. Int J Med Sci. 2022; 19(2):377-392. PMC: 8795799. DOI: 10.7150/ijms.69060. View

13.

Lin W, Chen W, Zhong J, Ueki H, Xu A, Watanabe M . Identification of MICALL2 as a Novel Prognostic Biomarker Correlating with Inflammation and T Cell Exhaustion of Kidney Renal Clear Cell Carcinoma. J Cancer. 2022; 13(4):1214-1228. PMC: 8899381. DOI: 10.7150/jca.66922. View

14.

Situ Y, Xu Q, Deng L, Zhu Y, Gao R, Lei L . System analysis of in renal cell carcinoma: The expression, prognosis, gene regulation network and regulation targets. Int J Biol Markers. 2021; 37(1):90-101. DOI: 10.1177/17246008211063501. View

15.

Xu H, Zheng X, Zhang S, Yi X, Zhang T, Wei Q . Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma. Mol Cancer. 2021; 20(1):159. PMC: 8645676. DOI: 10.1186/s12943-021-01465-w. View

16.

Mifflin L, Ofengeim D, Yuan J . Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020; 19(8):553-571. PMC: 7362612. DOI: 10.1038/s41573-020-0071-y. View

17.

Wu Y, Dong G, Sheng C . Targeting necroptosis in anticancer therapy: mechanisms and modulators. Acta Pharm Sin B. 2020; 10(9):1601-1618. PMC: 7563021. DOI: 10.1016/j.apsb.2020.01.007. View

18.

Duan Y, Zhang D . Identification of novel prognostic alternative splicing signature in papillary renal cell carcinoma. J Cell Biochem. 2019; 121(1):672-689. DOI: 10.1002/jcb.29314. View

19.

Yang F, Zhao G, Ge L, Song Y, Hong K, Zhang H . Identification of a Two-m6A RNA Methylation Regulator Risk Signature as an Independent Prognostic Biomarker in Papillary Renal Cell Carcinoma by Bioinformatic Analysis. Biomed Res Int. 2021; 2021:4582082. PMC: 7884118. DOI: 10.1155/2021/4582082. View

20.

Zhou X, Qiu S, Jin D, Jin K, Zheng X, Yang L . Development and Validation of an Individualized Immune-Related Gene Pairs Prognostic Signature in Papillary Renal Cell Carcinoma. Front Genet. 2020; 11:569884. PMC: 7680997. DOI: 10.3389/fgene.2020.569884. View